SHL Telemedicine Board Shake-Up: 4 Directors, Including Ehud Barak, Not Seeking Re-election

TL;DR

**SHL Telemedicine is getting a new board, with four directors stepping down and two new ones proposed.**

AI Summary

SHL Telemedicine Ltd. announced on February 5, 2024, that four current board members—Erez Nachtomy, David Salton, Erez Alroy, and Co-Chairman Ehud Barak—will not seek re-election at the upcoming Annual General Meeting on February 8, 2024. This significant change means nearly half of the non-external directors are stepping down, with new nominees Ido Nouberger and Nir Rotenberg proposed to join the board. This matters to investors because a substantial board refresh can signal a shift in company strategy or governance, potentially impacting future performance and shareholder value.

Why It Matters

A major change in board composition can signal a shift in company direction or a response to performance, directly influencing investor confidence and future strategic decisions.

Risk Assessment

Risk Level: medium — Significant board turnover can introduce uncertainty regarding future leadership and strategic direction, posing a moderate risk to investors.

Analyst Insight

A smart investor would monitor the outcomes of the February 8, 2024, Annual General Meeting and subsequent company announcements for insights into the new board's strategic direction before making significant investment decisions.

Key Players & Entities

• SHL Telemedicine Ltd. (company) — registrant
• Erez Nachtomy (person) — current Board of Directors member not seeking re-election
• David Salton (person) — current Board of Directors member not seeking re-election
• Erez Alroy (person) — current Board of Directors member not seeking re-election
• Ehud Barak (person) — current Co-Chairman and Board of Directors member not seeking re-election
• Yariv Alroy (person) — current Co-Chairman and director up for re-election
• Professor Amir Lerman (person) — current director up for re-election
• Yehoshua (Shuky) Abramovich (person) — external director whose term is not expiring
• Dvora Kimhi (person) — external director whose term is not expiring
• Ido Nouberger (person) — new director-nominee

Forward-Looking Statements

• The new board composition will lead to a strategic review of SHL Telemedicine's core business operations. (SHL Telemedicine Ltd.) — medium confidence, target: 2024-12-31
• Investor sentiment towards SHL Telemedicine will remain neutral until the impact of the new board is clearer. (SHL Telemedicine Ltd.) — high confidence, target: 2024-06-30

FAQ

Filing Documents

• zk2430874.htm (6-K) — 10KB
• 0001178913-24-000369.txt ( ) — 11KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41641 SHL TELEMEDICINE LTD. (Translation of registrant's name into English) 90 Yigal Alon Street Tel Aviv 67891, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F INFORMATION CONTAINED IN THIS FORM 6-K REPORT On February 5, 2024, SHL Telemedicine Ltd. (the "Company") announced that in connection with its upcoming 2023 Annual General Meeting of Shareholders (the "Meeting") to be held on Thursday, February 8, 2024, each of Erez Nachtomy, David Salton, Erez Alroy and our Co-Chairman Ehud Barak, current members of the Company's Board of Directors, have decided not to seek re-election at the Meeting. As set forth in the Notice and Proxy Statement filed by the Company in connection with the Meeting with the Securities and Exchange Commission on December 28, 2023, proposal 2 on the agenda of the Meeting is the approval of the re-election of our six current directors (not including the Company's two external directors, Yehoshua (Shuky) Abramovich and Dvora Kimhi, whose terms of office are not expiring at the Meeting and who are not up for reelection at the Meeting), which includes each of the four directors mentioned above, as well as our Co-Chairman Yariv Alroy and Professor Amir Lerman. As also set forth in the Notice and Proxy Statement, proposals 3 and 4 on the agenda of the Meeting is the approval of the election of each of our new director-nominees Ido Nouberger and Nir Rotenberg, respectively, and our Board has recommended that shareholders approve the election of the new director-nominees. In light of the proposed election of the new director-nominees, and in an attempt to further the goal of continuously refreshing the Company's Board of Directors, each of Erez Nachtomy, David Salton and Erez Alroy have decided not to seek re-election, and accordingly their nominations for re-election will be withdrawn at the Meeting. Mr. Nachtomy will remain as the Company's Chief Executive Officer and will remain engaged with the Board of Directors and benefit from the different perspectives, experience and qualifications that the new director-nominees will bring to the Board if elected. Mr. Barak has decided not to seek re-election as a director in order to pursue different professional and personal interests and not due to any disagreement with the Company, and accordingly his nomination for re-election will also be withdrawn at the Meeting. Except as set forth above, there are no changes to the agenda of the Meeting and the Meeting will proceed as schedule, and the Company will not be amending and re-circulating a revised Notice and Proxy Statement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SHL Telemedicine Ltd. By: /s/ Amir Hai Amir Hai Chief Financial Officer February 5, 2024

View Full Filing

View this 6-K filing on SEC EDGAR